From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development
Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…
CertaraApril 28, 2026
ADC Dose Optimization: Applying Model-Informed Strategies in Development
Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…
CertaraApril 22, 2026
Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body
JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 16, 2026 When I first began learning about pharmacokinetics (PK), I was often…
CertaraApril 16, 2026
PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)
Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…
CertaraApril 9, 2026
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
This study demonstrates how a model-informed, totality-of-evidence approach was used to select the optimal clinical…
Danielle PillsburyApril 2, 2026
Where Did the 80-125% Bioequivalence Criteria Come From?
Discover what bioequivalence criteria mean, why the 80-125% bioequivalence range is used, and how custom…
CertaraMarch 27, 2026
Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection
PK/PD Modeling for CNS drug development using Phoenix NLME and machine learning for better CNS…
CertaraMarch 26, 2026
